Following are selected peer-reviewed publications resulting from research made possible by grants from the Glaucoma Research Foundation. Peer review is a scholarly process used in the publication of scientific research manuscripts. Peer review insures high quality standards by subjecting an author's work or ideas to the scrutiny of others who.
Cannabis Research for Glaucoma. Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness. However, with early detection and treatment, you can often protect your eyes against serious vision loss. Several large studies have shown that eye pressure is a major risk factor for optic nerve damage. In the front of the eye is a space called the.
Cannabis and Cannabinoid Research is the premier journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids.The Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical.Research Progress. For more than 40 years, the Glaucoma Research Foundation has funded innovative clinical and laboratory research. We’ve done so thanks to the help and dedication of the community, who have stood by and supported us in our mission to makes lives better and to find a cure. With your continued financial support and involvement, we will continue to lead the way in research.The purpose of this article is to provide the reader with an overview of the latest achievements in research into the potential use of cannabinoids for glaucoma. Discover the world's research 17.
Glaucoma is one of the leading causes of blindness in the world. In spite of the diverse therapeutic possibilities, new and better treatments for glaucoma are highly desirable. Cannabinoids effectively lower the intraocular pressure (IOP) and have neuroprotective actions. Thus, they could potentially be useful in the treatment of glaucoma. The purpose of this article is to provide the reader.
CALL FOR PAPERS: Special Issue on Cannabinoids and the Immune System Briefings in Cannabis and Cannabinoid Research - a free, comprehensive news source delivered monthly Sign up now View the archive. Cannabis and Cannabinoid Research receives a 3.1 CiteScore. Cannabis and Cannabinoid Research is now fully indexed in PubMed Central and fully searchable on PubMed.
Researchers are currently developing modes of treatments that would use these cannabinoid properties to treat glaucoma patients. The Neuroprotective Properties of Cannabinoids. The full mechanism of action of cannabinoids in the human eye is not fully understood. A lot of research has demonstrated that cannabinoids enhance survival of neurons in neurodegenerative diseases. In glaucoma, for.
The discovery of ocular cannabinoid receptors implied an explanation for the induction of hypotension by topical cannabinoid applications, and has stimulated a new phase of ophthalmic cannabinoid research. Featured within these investigations is the possibility that at least some cannabinoids may ameliorate optic neuronal damage through suppression of N-methyl-D-aspartate receptor.
Which is good, because the only chemovar that can currently assist glaucoma may just be a high THC variety. No excuses required, unless it is possible the inactive cannabinoid, THCa can be used for eye injury instead. Stay tuned to find out why this cannabinoid is so unique. Photo courtesy of NEJM. Sources. Arch Dermatol Res. 2019 Jul;311(5.
New research into CBD for glaucoma, however, reveals that cannabidiol could potentially function as a highly effective new therapeutic treatment method. The most common type of glaucoma is called open-angle glaucoma, followed by less common types of the condition such as closed-angle glaucoma and normal-tension glaucoma.
This chapter focuses on the effects of cannabinoids on intraocular pressure (IOP), a major risk factor in the development of glaucoma. A review of original papers, published in English and indexed in PubMed up to Jun., 2014, is discussed in this chapter. All three classes of cannabinoids, including phytocannabinoids, synthetic cannabinoids, and.
Cannabinoids for treatment of glaucoma. Novack, Gary D. Current Opinion in Ophthalmology: March 2016 - Volume 27. Summary The pharmacology of marijuana and its effect on intraocular pressure has not changed since the research in the 1970s and 1980s. Marijuana is an effective ocular hypotensive agent. However, cardiovascular and neurological effects are observed at the same dose, and may.
According to research results since 1970s, both THC and marijuana lessens intraocular pressure which is a primary triggering factor to the development of glaucoma. Considerable interest has been generated by first reports because at that time, regular medications for the disease have led to different side effects. Glaucoma is one of the primary causes of blindness around the world, which.
Disease DescriptionGlaucoma is a disease in which the optic nerve is damaged, leading to progressive, irreversible loss of vision. It is often, but not always, associated with increased pressure of the fluid in the eye.The nerve damage involves loss of retinal ganglion cells in a characteristic pattern. There are many different sub-types of glaucoma but they can all be considered as a type of.
Despite the findings from early research, few ophthalmologists support the use of medical marijuana for patients with early to mid-stage glaucoma. The main issue ophthalmologists have is that potential adverse effects —particularly when smoking weed—might outweigh short-term benefits. For example, smoking can lead to unstable intraocular pressure, thereby increasing the risk of permanent.